[1
]
From the Department of Pediatric Neurology, Catholic University, Rome (E.M., E.S.M.);
the Department of Neurology, Boston Children's Hospital, Boston (B.T.D.), and Biogen,
Cambridge (R.F., S.G., W.F.) - both in Massachusetts; the Departments of Neurology
(C.A.C., J.M., D.C.D.), Pediatrics (C.A.C., D.C.D.), and Rehabilitation and Regenerative
Medicine (J.M.), Columbia University Medical Center, New York; the Department of Neurology,
Stanford School of Medicine, Stanford (J.W.D.), David Geffen School of Medicine at
University of California, Los Angeles, Los Angeles (P.B.S.), and Ionis Pharmaceuticals,
Carlsbad (K.M.B., Q.Y., C.F.B., E.S.) - all in California; Children's Hospital-London
Health Sciences Centre, London, ON, Canada (C.C.); the Department of Neurology, Washington
University School of Medicine, St. Louis (A.M.C.); the Department of Pediatrics, University
of Texas Southwestern Medical Center, Dallas (S.T.I.); the Department of Neuropediatrics
and Muscle Disorders, Medical Center-University of Freiburg, Faculty of Medicine,
Freiburg, Germany (J.K.); the Department of Pediatrics, Ann and Robert H. Lurie Children's
Hospital, Chicago (N.L.K.); the Institute of Medical Genetics and Department of Pediatrics,
Tokyo Women's Medical University, Tokyo (K.S.); the Department of Pediatrics, Gothenburg
University, Queen Silvia Children's Hospital, Gothenburg, Sweden (M.T.); and the Division
of Neurology, Department of Pediatrics, Nemours Children's Hospital, Orlando, FL (R.S.F.).